Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 2
2004 1
2014 1
2015 1
2017 1
2018 1
2020 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P; ETHOS Investigators. Rabe KF, et al. N Engl J Med. 2020 Jul 2;383(1):35-48. doi: 10.1056/NEJMoa1916046. Epub 2020 Jun 24. N Engl J Med. 2020. PMID: 32579807 Clinical Trial.
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR, Turgeon AF, Escobedo J, Huang DT, Bradbury CA, Houston BL, Kornblith LZ, Kumar A, Kahn SR, Cushman M, McQuilten Z, Slutsky AS, Kim KS, Gordon AC, Kirwan BA, Brooks MM, Higgins AM, Lewis RJ, Lorenzi E, Berry SM, Berry LR, Aday AW, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Costantini TW, de Brouwer S, Derde LPG, Detry MA, Duggal A, Džavík V, Effron MB, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Galanaud JP, Galen BT, Gandotra S, García-Madrona S, Girard TD, Godoy LC, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Hamburg NM, Haniffa R, Hanna G, Hanna N, Hegde SM, Hendrickson CM, Hite RD, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Hudock K, Hunt BJ, Husain M, Hyzy RC, Iyer VN, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski AL, King AJ, Knudson MM, Kornblith AE, Krish… See abstract for full author list ➔ ATTACC Investigators, et al. N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4. N Engl J Med. 2021. PMID: 34351721 Free PMC article. Clinical Trial.
Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure.
Barbie DA, Spira A, Kelly K, Humeniuk R, Kawashima J, Kong S, Koczywas M. Barbie DA, et al. Clin Lung Cancer. 2018 Nov;19(6):e853-e859. doi: 10.1016/j.cllc.2018.07.004. Epub 2018 Aug 4. Clin Lung Cancer. 2018. PMID: 30087028 Free PMC article. Clinical Trial.
INTRODUCTION: Specific treatment options are lacking for Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated non-small-cell lung cancer (NSCLC) despite treatment advances in other mutation-driven subgroups. ...
INTRODUCTION: Specific treatment options are lacking for Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated non-small-cell lun …
Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results.
Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim EJ, Gong IY, Tanaka M, Beckett L, Holland W, Burich RA, Snyder-Solis L, Mack P, Lara PN Jr. Semrad T, et al. Int J Clin Oncol. 2015 Jun;20(3):518-24. doi: 10.1007/s10147-014-0730-2. Epub 2014 Aug 5. Int J Clin Oncol. 2015. PMID: 25091263 Free PMC article.
METHODS: Patients with measurable, previously untreated locally advanced unresectable or metastatic pancreatic cancer were treated with gemcitabine 1000 mg/m(2) as an intravenous infusion over 30-min on days 1, 8, 15 and erlotinib 150 mg/day on days 2-5, 9-12, 16-26 of eac …
METHODS: Patients with measurable, previously untreated locally advanced unresectable or metastatic pancreatic cancer were treated with gemc …
Targeted Assessment and Context-Tailored Implementation of Change Strategies (TACTICS) to increase evidence based psychotherapy in military behavioral health clinics: Design of a cluster-randomized stepped-wedge implementation study.
Rosen CS, Davis CA, Riggs D, Cook J, Peterson AL, Young-McCaughan S, Comtois KA, Haddock CK, Borah EV, Dondanville KA, Finley EP, Jahnke SA, Poston WSC, Wiltsey-Stirman S, Neitzer A, Broussard CR, Brzuchalski MA, Clayton MSP, Conforte LAM, Flores A, Hein J, Keith CF, Jinkerson CJ, Letendre M, Nofziger D, Pollick K, Santiago CK, Waggoner LCJ, Woodworth C, McLean CP; TACTICS Research Group. Rosen CS, et al. Contemp Clin Trials. 2020 Jun;93:106008. doi: 10.1016/j.cct.2020.106008. Epub 2020 Apr 21. Contemp Clin Trials. 2020. PMID: 32330670
Effects of nicotine and mecamylamine on cognition in rhesus monkeys.
Katner SN, Davis SA, Kirsten AJ, Taffe MA. Katner SN, et al. Psychopharmacology (Berl). 2004 Sep;175(2):225-40. doi: 10.1007/s00213-004-1804-z. Epub 2004 Apr 27. Psychopharmacology (Berl). 2004. PMID: 15112030 Free PMC article.
METHODS: Rhesus monkeys (n=6) were trained to perform a battery of six behavioral tasks and then serially challenged with acute doses of nicotine (3.2-56 microg/kg, i.m.) and the nAChR antagonist mecamylamine (0.32-1.78 mg/kg, i.m.). ...
METHODS: Rhesus monkeys (n=6) were trained to perform a battery of six behavioral tasks and then serially challenged with acute doses of nic …
Evaluation of Placental and Fetal Tissue Specimens for Zika Virus Infection - 50 States and District of Columbia, January-December, 2016.
Reagan-Steiner S, Simeone R, Simon E, Bhatnagar J, Oduyebo T, Free R, Denison AM, Rabeneck DB, Ellington S, Petersen E, Gary J, Hale G, Keating MK, Martines RB, Muehlenbachs A, Ritter J, Lee E, Davidson A, Conners E, Scotland S, Sandhu K, Bingham A, Kassens E, Smith L, St George K, Ahmad N, Tanner M, Beavers S, Miers B, VanMaldeghem K, Khan S, Rabe I, Gould C, Meaney-Delman D, Honein MA, Shieh WJ, Jamieson DJ, Fischer M, Zaki SR; U.S. Zika Pregnancy Registry Collaboration; Zika Virus Response Epidemiology and Surveillance Task Force Pathology Team. Reagan-Steiner S, et al. MMWR Morb Mortal Wkly Rep. 2017 Jun 23;66(24):636-643. doi: 10.15585/mmwr.mm6624a3. MMWR Morb Mortal Wkly Rep. 2017. PMID: 28640798 Free PMC article.
Zika virus RT-PCR was positive on placental tissues from 38/363 (10%) live births with maternal serologic evidence of recent unspecified flavivirus infection and from 9/86 (10%) with negative maternal Zika virus immunoglobulin M (IgM) where possible maternal exposure occur …
Zika virus RT-PCR was positive on placental tissues from 38/363 (10%) live births with maternal serologic evidence of recent unspecified fla …
Structural specificity and tumoricidal action of methyl-3,5-diiodo-4-(4'-methoxyphenoxy) benzoate (DIME).
Mendeleyev J, Young L, Kirsten E, Vidair C, Hakam A, Zhen J, Bauer P, Buki K, Kun E. Mendeleyev J, et al. Int J Oncol. 1997 Apr;10(4):689-95. doi: 10.3892/ijo.10.4.689. Int J Oncol. 1997. PMID: 21533432
Inhibition of clonogenicity with MDA-MB-231 cells by DIME yielded I-50 values similar to those found in tests measuring cell growth inhibition (median I-50 less than 1.0 mu M) The apparent ultimate signal for cytocidal action of DIME is the development of dose-dependent do …
Inhibition of clonogenicity with MDA-MB-231 cells by DIME yielded I-50 values similar to those found in tests measuring cell growth inhibiti …
Cellular analysis of the mode of action of methyl-3,5-diiodo-4-(4'-methoxyphenoxy) benzoate (DIME) on tumor cells.
Zhen J, Feuerstein B, Vidair C, Hyun W, Young L, Kirsten E, Kun E. Zhen J, et al. Int J Oncol. 1997 May;10(5):905-10. doi: 10.3892/ijo.10.5.905. Int J Oncol. 1997. PMID: 21533461
The hormonally inactive methyl-3,5-diiodo-4-(4'-methoxyphenoxy) benzoate (DIME) at 1-4 mu M concentration induces morphologic changes in E-ras 20 and MDA-MB-231 and other human cancer cells such as multinucleation and enlargement and arrests the cell cycle in the M …
The hormonally inactive methyl-3,5-diiodo-4-(4'-methoxyphenoxy) benzoate (DIME) at 1-4 mu M concentration induces morphologic changes …
Modification of growth related enzymatic pathways and apparent loss of tumorigenicity of a ras-transformed bovine endothelial cell line by treatment with 5-iodo-6-amino-1,2-benzopyrone (INH2BP).
Bauer P, Kirsten E, Young L, Varadi G, Csonka E, Buki K, Mikala G, Hu R, Comstock J, Mendeleyev J, Hakam A, Kun E. Bauer P, et al. Int J Oncol. 1996 Feb;8(2):239-52. doi: 10.3892/ijo.8.2.239. Int J Oncol. 1996. PMID: 21544352
Sustained pretreatment with a non-cytotoxic concentration (600 mu M) of 5-iodo-6-amino-1,2-benzopyrone (INH2BP), a lipophilic ligand of poly(ADP-ribose) polymerase, abrogated in vivo tumorigenicity, of 10(5) cells per inoculum an effect which developed progressively during …
Sustained pretreatment with a non-cytotoxic concentration (600 mu M) of 5-iodo-6-amino-1,2-benzopyrone (INH2BP), a lipophilic ligand …